aTyr Pharma, Inc.(US:ATYR) Prnewswireยท2025-10-15 14:24Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against aTyr Pharma, Inc. due to allegations of misleading statements regarding the efficacy of its drug Efzofitimod, which led to significant financial losses for investors [1][3]. Company Overview - aTyr Pharma, Inc. is a biopharmaceutical company whose stock has recently experienced a dramatic decline following the release of clinical trial results for Efzofitimod [1][4]. Legal Proceedings - A federal securities class action has been filed against aTyr, with a deadline of December 9, 2025, for investors to seek the role of lead plaintiff [1][5]. - The complaint alleges that aTyr and its executives violated federal securities laws by making false and misleading statements about the drug's capabilities [3][4]. Clinical Trial Results - In the EFZO-FIT study, Efzofitimod did not demonstrate a significant reduction in mean daily oral corticosteroid (OCS) dose compared to placebo, with a reduction of 2.79 mg for the drug versus 3.52 mg for placebo [4]. - Complete steroid withdrawal was achieved in 52.6% of patients treated with Efzofitimod compared to 40.2% on placebo [4]. Stock Performance - Following the release of the clinical trial results, aTyr's stock plummeted by 83.25%, dropping from a market close of $6.03 on September 12 to $1.01 on September 15 [4].